|
1. Biologie
|
|
|
|
5. Traitements
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
Critics of experimental cancer therapy just don’t get it [STAT]
|
|
|
|
|
|
Zach
experienced horrendous side effects from his chemotherapy, died from
treatment-related complications, and the cost was astronomical — but all
of this was with “standard” cancer therapy. In my view, the critics of
CAR-T therapy are taking a myopic view of this incredibly powerful and
exciting form of cancer treatment, one that holds great hope for
desperate patients and their families.
|
|
|
|
|
|
|
5.2.2 Pharma - Fusions & Acquisitions
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
Transparency Push: EMA to Revise Policy on Document Access [RAPS]
|
|
|
|
|
|
EMA
is now seeking comments until 18 May on a revision that says: “The
information proactively published will be increased with the
introduction of proactive publication of clinical data for medicinal
products for human use (EMA Policy/0070) and with the coming into force
of other relevant legislative provisions.”
|
|
|
|
|
|
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
Generic version of top-selling lung cancer drug hits Chinese market [Pharmafile]
|
|
|
|
|
|
A
generic version of AstraZeneca’s Iressa (gefitinib) has been released
onto the Chinese market, named Yiruike. The generic undercuts the price
of Iressa drastically, with Iressa now being 5 times more expensive, and
offers to extend the lifesaving medication to those in need who
previously could not the cost of AstraZeneca's drug.
|
|
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.1 Observation
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
|
An IBM-Watson Collaboration Goes Under [In the Pipeline]
|
|
|
|
|
|
It’s
worth noting that there was good press about this effort along the way,
with stories about how well the software was doing at diagnosis, etc.
Something to consider when you come across stories written in the same
vein, for sure. Wait until the project delivers before making it down as
a success. . .
|
|
|
|